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A B S T R A C T
Background
Sodium cromoglycate has been recommended as maintenance treatment for childhood asthma for many years. Its use has decreased
since 1990, when inhaled corticosteroids became popular, but it is still used in many countries.
Objectives
To determine the efficacy of sodium cromoglycate compared to placebo in the prophylactic treatment of children with asthma.
Search methods
We searched the Cochrane Airways Group Trials Register (October 2009), the Cochrane Central Register of Controlled Trials (CEN-
TRAL) (The Cochrane Library Issue 3, 2009), MEDLINE (January 1966 to October 2009), EMBASE (January 1985 to October 2009)
and reference lists of articles. We also contacted the pharmaceutical company manufacturing sodium cromoglycate.
Selection criteria
All double-blind, placebo-controlled randomised trials, which addressed the effectiveness of inhaled sodium cromoglycate as mainte-
nance therapy, studying children aged 0 up to 18 years with asthma.
Data collection and analysis
Two authors independently assessed trial quality and extracted data. We pooled study results.
Main results
Of 3500 titles retrieved from the literature, 24 papers reporting on 23 studies could be included in the review. The studies were
published between 1970 and 1997 and together included 1026 participants. Most were cross-over studies. Few studies provided
sufficient information to judge the concealment of allocation. Four studies provided results for the percentage of symptom-free days.
Pooling the results did not reveal a statistically significant difference between sodium cromoglycate and placebo. For the other pooled
outcomes, most of the symptom-related outcomes and bronchodilator use showed statistically significant results, but treatment effects
were small. Considering the confidence intervals of the outcome measures, a clinically relevant effect of sodium cromoglycate cannot
be excluded. The funnel plot showed an under-representation of small studies with negative results, suggesting publication bias.
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Authors’ conclusions
There is insufficient evidence to be sure about the efficacy of sodium cromoglycate over placebo. Publication bias is likely to have
overestimated the beneficial effects of sodium cromoglycate as maintenance therapy in childhood asthma.
P L A I N L A N G U A G E S U M M A R Y
The effects of sodium cromoglycate compared with placebo for chronic asthma in children
In this review we aimed to determine whether there is evidence for the effectiveness of inhaled sodium cromoglycate as maintenance
treatment in children with chronic asthma. Most of the studies were carried out in small groups of patients. Furthermore, we suspect
that not all studies undertaken have been published. The results show that there is insufficient evidence to be sure about the beneficial
effect of sodium cromoglycate compared to placebo. However, for several outcome measures the results favoured sodium cromoglycate.
B A C K G R O U N D
Since the late 1960s, disodium cromoglycate (DSCG) has been
used asmaintenance treatment for childrenwithmoderate asthma,
although the precise mechanism of action is still not fully under-
stood. No serious side effects have been reported in trials, but cases
of dysuria, urticaria, bronchospasm, angio-oedema and anaphy-
laxis have been ascribed to the use of DSCG, once with death as
a result (Lester 1997; Leynadier 1985).
In the early 1990s, many guidelines recommended use of DSCG.
Gradually, corticosteroids have come to the fore as first choice
maintenance therapy (BAG 1997; Ernst 1996), or were recom-
mended alongside DSCG for mild persistent asthma (NIH 1997).
Other guidelines continued to recommend DSCG as first choice
in young children (Sly 1997). The most recent revisions of the
GINA and NIH guidelines (GINA 2005; NIH 2002) consider
the role of DSCG in children to be limited. Inhaled glucocorti-
costeroids are the first choice; DSCG is only recommended as one
of the alternative treatment options for children with mild persis-
tent asthma. Canadian guidelines no longer recommend DSCG
as maintenance therapy for children, nor do British guidelines for
children aged 5 to 12 years (Becker 2005; BTS 2003, page i20).
The long-term side effects of asthma treatment with inhaled
steroids in early childhood are not clear. Nevertheless, there is con-
cern that treating very mild cases of asthma with inhaled steroids
may have an adverse effect on the balance between risk and benefit.
A Cochrane review has shown an effect of inhaled beclomethasone
on linear growth in children (Sharek 1999). Therefore, physicians
involved in the treatment of asthma in children may still prefer
sodium cromoglycate as first choice maintenance treatment.
The use of DSCG has decreased since 1990, while the use of
inhaled corticosteroids is increasing. The discrepancy between
guidelines and the debate on the role of DSCG, which led to its
recent withdrawal as first line maintenance treatment in young
children in some countries, was the rationale to review the efficacy
of inhaledDSCGasmaintenance treatment for chronic childhood
asthma.
O B J E C T I V E S
To determine whether there is evidence for the efficacy of inhaled
sodium cromoglycate as maintenance treatment in children with
asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All double-blind, placebo-controlled, randomised clinical trials,
which addressed the effectiveness of DSCG as maintenance ther-
apy.
Types of participants
Children aged 0 up to 18 years with asthma in all settings (general
practice, emergency departments, outpatient departments, hospi-
talised). We only included studies including both children and
adults when results for children were presented separately. When
2Inhaled sodium cromoglycate for asthma in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the number of children in these studies was less than five, we did
not include the study.
Types of interventions
Inhaled sodium cromoglycate, delivered via any device: nebulised,
by Spinhaler or by metered dose inhaler, with or without hold-
ing chamber. We only included trials that compared DSCG with
placebo. No co-interventions were permitted other than rescue
medication as needed.
Types of outcome measures
Primary outcomes
The primary outcome measure was the difference in percentage
of days without asthma symptoms, between placebo and cromo-
glycate treatment.
Secondary outcomes
• Symptom scores (day cough, day wheeze, daytime asthma
score, day activity, night cough, night wheeze, night-time asthma
score, sleep disturbance, overall symptom/severity score)
• Auscultation score
• Preference of patients/parents and clinicians
• Overall success rate
• Bronchodilator use, use of oral steroids, hospital admission
• Side effects
Search methods for identification of studies
Electronic searches
Trials were identified using the Cochrane Airways Group Spe-
cialised Register of trials, which is derived from systematic searches
of bibliographic databases including the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respira-
tory journals andmeeting abstracts (please see the Airways Group
Module for further details).
Additonal searches of theCochraneCentral Register of Controlled
Trials (CENTRAL) (The Cochrane Library Issue 3, 2009), MED-
LINE (January 1966 to October 2009) and EMBASE (1979 to
October 2009) were also conducted. For MEDLINE and EM-
BASE we used the Cochrane sensitive search strategy to select all
RCTs (Dickersin 1994) and in all databases, we used the following
search terms:
cromolyn* OR dscg OR cromoglycate* or cromoglicate* OR
cromone* or intal*
Searches are current to October 2009.
Searching other resources
We contacted the pharmaceutical companymanufacturingDSCG
(Rhone-Poulenc-Rorer, formerly Fisons plc, Loughborough, UK),
checked bibliographies of retrieved trials and contacted primary
authors of trials published after 1990 for any additional trials.
Data collection and analysis
Data extraction and management
Two authors extracted data. When using symptom scores, most
studies used a scale of 0 to 3 points; where a different scale was
used we transformed themean and standard deviation for our pur-
poses. We calculated confidence intervals for the treatment effect
(difference in symptom score) for individual studies assuming a t-
distribution.
Assessment of risk of bias in included studies
Two authors independently scored the methodological quality of
all trials using three sets of criteria: Chalmers (Chalmers 1981),
Jadad (Jadad 1996) and the Cochrane criteria for concealment.
A third author determined the final decision if there was lack of
consensus. Trials in which one of the authors was involved were
also scored by an impartial author. We did not contact authors
of the trials for confirmation of methodology and data extraction,
because most of the studies were performed many years ago and
we considered it unlikely that this would provide further useful
information. When updating the review in 2007, a ’Risk of Bias’
table was added (Figure 1).
Dealing with missing data
If no standard error of the treatment effect of a particular outcome
measure was available, and could not be calculated, we imputed
it from a study with a similar design (cross-over or parallel) (cf
Follman 1999). If more than one study was available for imputa-
tion, we selected the largest study, unless this choice would lead
to inconsistencies with the results in the original study (e.g. when
the authors reported no significant difference, but the imputed
data would change this). In that case the second largest study was
taken.
Data synthesis
We computed pooled estimates of the treatment effect and the
pooled 95% confidence intervals (CI), combining parallel and
cross-over studies (Elbourne 2002). For cross-over studies we used
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the results of paired analyses, extracting treatment effect, standard
error and within patient correlation between DSCG and placebo
period (rho) from papers. When rho was not given, we imputed
this in the same way as stated above for missing standard errors.
We tested for homogeneity (Dersimonian 1986). When hetero-
geneity was found (P < 0.05), we did not use the fixed-effectmodel
to compute a pooled estimate and confidence interval, but only
used the random-effects model (Dersimonian 1986). To investi-
gate causes for heterogeneity, we evaluated the influence of study
characteristics (year of publication, mean age of children, method
of delivery, asthma severity of the study population, methodolog-
ical quality, doses per day and duration). Assessment of asthma
severity was based on the description of the study population in
the papers (see ’Characteristics of included studies’ table). As there
was no single outcomemeasure available for all studies, we selected
those outcomes for which at least 10 studies were available. To
include as many studies as possible in the funnel plot (see below)
and the meta-regression analysis, we combined various outcome
measures that used a similar scale, taking the first available from
overall symptom score, day wheeze, day cough, day activity and
daytime asthma score.
For all study characteristics except asthma severity, we usedunivari-
ate and multivariate meta-regression analysis (Fleiss 1993), weigh-
ing observations by the reciprocal of the square of the standard
error of the mean difference between placebo and DSCG. Thus,
all pooled outcomes are presented as weighted mean differences
(WMD). Study characteristics were either entered as categorical
(design, type of delivery) or as continuous (publication year, qual-
ity score, etc.). For asthma severity, we used the asthma score in
the placebo group (or period) as study characteristic. Because this
measurement is subject to measurement error as much as the out-
come variables are, ordinary regression analysis is inappropriate,
as this technique only assumes measurement error in the outcome
variable. Therefore, we used an analysis technique called func-
tional relationships (Nagelkerke 1992) to evaluate the influence
of asthma severity of the study population on the outcome for
cough, wheeze and overall symptom score.
We performed all analyses using SPSS version 10 for the initial
review.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analyses when outcome data were avail-
able from at least 10 studies, using the following characteristics for
subgroup identification: asthma severity (moderate versus severe),
health care settings (hospitalised/institutionalised versus other set-
tings), type of delivery (nebulised versus other), age (using a mean
age of five years as the cut-off point), duration of follow up (using
three months follow up as the cut-off point) and methodological
quality (for Jadad’s scoring system three points or higher versus
lower; for Chalmers’ summated items the 13 best studies versus
the remaining studies).
To explore heterogeneity further and visualise possible publication
bias, we constructed a funnel plot of the effect estimate (delta)
against the precision (Egger 1995), using the same combination of
outcome measures as for meta-regression analysis. The precision
of a trial was defined as one divided by the standard error. The
symmetry of the funnel plot was tested using a significance level
of 0.10 (Egger 1997).
R E S U L T S
Description of studies
Results of the search
Searching the literature databases resulted in retrieval of over 3500
titles (MEDLINE: 1500; EMBASE: 1400; Cochrane Airways
Group Trials Register: 850 titles). We read about 200 papers in
full; 65 of these were evaluated by two authors according to a struc-
tured inclusion criteria form. The final set consisted of 24 papers,
reporting on 23 studies. For one study, two papers were published
reporting on different outcome measures (Yuksel 1992). Update
searches were conducted in November 2006 and October 2007.
These identified 181 titles, which were screened, and 10 were ob-
tained as full papers for further assessment. None of these fulfilled
our inclusion criteria, but several were added to the list of excluded
studies. An updated search in October 2008 did not identify any
new studies for consideration in the review. The latest search was
in July 2010 and it did not return any eligible studies although
two studies were added to Characteristics of excluded studies.
Included studies
Most of the included studies were European (13 studies, nine of
which were from the UK) or North American. Two were from
Israel, three from Japan and one from Thailand. All but three
papers were written in English. One study was in Norwegian (
Dalene 1977), the other two in Japanese (Kobayashi 1970;Mikawa
1986).
The studies were published between 1970 and 1997. Twelve stud-
ies were published in the 1970s, eight studies in the 1980s, and
four in the 1990s. Detailed information on each study is given in
the table of ’Characteristics of included studies’.
The age range of the children in the included studies varied consid-
erably. Eleven studies included children not older than four years
of age. In one study (Easton 1973) the age of the children was
not specified. Before 1977, none of the studies included children
below the age of four.
Most of the studies had a cross-over design. Four were parallel
group studies. The cross-over studies typically were divided into
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two periods of three or four weeks treatment, with sometimes a
washout period in between. In some of the cross-over studies, the
first two weeks of each period were ignored in the analysis.
In nine studies the study drugs (DSCG or placebo) were nebu-
lised. Nine studies used dry powder in capsules, most often with
the Spinhaler as device, but sometimes without a device being
mentioned. In five studies the drugs were administered as aerosols
with a spacer and sometimes a facemask.
In several papers it was not clear whether and what concurrent
medicationwas permitted during the trial.We included these stud-
ies. Compliance with the therapy regimen was only discussed in a
minority of papers.
Most of the studies were carried out in a hospital setting, usually
with outpatients. For several studies, no information about the
setting could be found. Based on the authors’ affiliations, we as-
sumed that these were hospital outpatients. In these cases we have
added a question mark after ’hospital outpatients’ in the table of
study characteristics. Only one study recruited patients in general
practice (Tasche 1997).
Regarding asthma severity, most of the studies included children
that would be classified as having moderate or severe asthma by
current standards (e.g. GINA 2005). Many children had one or
more hospital admissions for asthma in the past. The three studies
with probably the largest proportion of mild asthmatic children
were Edmunds 1980; Furfaro 1994 and Tasche 1997.
The size of the trials varied between 10 and 232 participants.
Only two trials included more than 100 children (Mikawa 1986;
Tasche 1997). As can be expected, the parallel-group trials had
larger patient groups than the cross-over trials (parallel group trials
had on average 131 participants versus 26 for cross-over studies).
Altogether, the 23 studies included 1026 participants.
The length of the period during which the children used either
active medication or placebo in the trials varied from three weeks
to 26 weeks. For 15 studies (of which 14 had a cross-over design),
this was three or four weeks, while only two studies had a duration
of over 10 weeks (Cogswell 1985; Tasche 1997).
Several study characteristics were strongly correlated. Dose (cor-
rected for type of delivery),method of delivery, year of publication,
age of children and length of treatment period showed Pearson
correlations up to 0.75.
The variety of outcome measures on which data were reported
was large. Likewise, for most outcome measures only few studies
reported comparable data. The outcome measures that were re-
portedmost oftenwere asthma scores (10 studies), daytimewheeze
scores (10 studies), daytime cough scores (nine studies) and bron-
chodilator use (10 studies). Several studies reporting on hospital
admittance and steroid use provided insufficient information to
be included in the pooled results.
Excluded studies
Excluded studies were either not blinded, not randomised, not
placebo-controlled, did not concern the appropriate age group,
or investigated the effectiveness of DSCG in exercise induced
asthma. One study (Kraemer 1993) was misclassified and hence
erroneously included in the first version of the review: this trial
was removed from this update (see ’Characteristics of excluded
studies’).
Risk of bias in included studies
See: table ’Characteristics of included studies’.
The methodological quality, as assessed by two scoring methods,
varied considerably (see Table 1; Table 2). Only one study attained
themaximum score of five points on the Jadad list (Mikawa 1986).
The proportion of items fulfilled on Chalmers’s list varied between
24 and79%(mean44% (SD11.9)).Of the papers reporting cross-
over studies, only few stated explicitly that the sequence of both
treatments had been randomised. In the analysis, we assumed they
were.
When updating the review in 2007, ’Risk of Bias’ tables were
produced, and a summary table was added to this review (Figure
1). For further explanationof this table, see theCochrane Handbook
for Systematic Reviews of Interventions, Chapter 8 (Higgins 2008).
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Figure 1. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included study.
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For several items (sequence generation, allocation concealment,
selective reporting and other sources of bias), only few studies
provided a clear answer. The proportion of question marks (for
which the study reports do not provide enough information) is
high. Blinding was considered to be adequate for all studies, which
is no surprise, as this was an inclusion criterion. Several studies
inadequately reported on incomplete outcome data or reported
selectively. None of the studies attained the maximum score for
’withdrawals’, and 20 of the 23 studies scored less than 50% on
this item (Table 1).
Effects of interventions
Study outcomes have been gathered into Additional tables 3 to 19
and summarised in Table 20. The tables give pooled point esti-
mates for the difference between DSCG and placebo (i.e. DSCG
minus placebo), and confidence intervals, assuming homogene-
ity (fixed-effect) and heterogeneity (random-effects). Below we re-
port the results for the outcome measures for which a considerable
number of studies were available. These study outcomes are now
also shown as forest plots for the primary outcome measure and
all secondary outcomes with more than five contributing studies.
Symptoms
Only four studies provided results for the percentage of symptom-
free days: our primary outcome measure (Figure 2; Table 3). In
all but one of the studies (Cogswell 1985), the confidence interval
included the point of no difference. Pooling the results revealed no
significant difference between DSCG and placebo (WMD 6.76%
favouring DSCG, 95%CI -2.18 to 15.70), random-effects model.
Figure 2. Forest plot of the primary outcome of the review: mean difference in % symptom-free days
between sodium cromoglycate and placebo
A variety of other symptom and hindrance scores was found. In
tables 4 to 19 we present the results for outcome measures for
which at least two studies provided data. Here we describe the
results for the symptom scores with the largest number of studies:
day cough score (nine studies), day wheeze score (10 studies), and
overall symptom/severity score (10 studies).
For daytime cough, the difference between placebo and DSCG
favoured DSCG in all but one study (Bertelsen 1986) (Figure 3;
Table 4). The confidence intervals included the point of no dif-
ference for seven out of the nine studies. Pooling the results (ran-
dom-effects model because of heterogeneity) did result in a statis-
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tically significant difference between placebo and DSCG favour-
ing DSCG (WMD -0.18, 95% CI -0.32 to -0.04).
Figure 3. Forest plot of mean difference in symptom scores for day cough between sodium cromoglycate
and placebo
For daytime wheeze the pooled results show a small but significant
difference favouring DSCG: a difference of -0.11 (WMD) on a
scale of 0 to 3 (95% CI -0.19 to -0.03; random-effects model)
(Figure 4; Table 5).
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Figure 4. Forest plot of mean difference in symptom scores for day wheeze between sodium cromoglycate
and placebo
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Mean overall symptom scores favoured DSCG in direction in six
out of ten studies (Figure 5;Table 6). The 95%confidence intervals
of four of the studies included the point of no difference. Pooling
the results (test of homogeneity rejected, hence random-effects
model) showed an overall mean difference of -0.22 symptom score
points (WMD), favouring the DSCG group (95%CI -0.34 to -
0.09), hence statistically significant.
Figure 5. Forest plot of mean difference in overall symptoms between sodium cromoglycate and placebo
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Use of other medication
The use of bronchodilators was reported in ten studies (Figure 6;
Table 7). Seven of these reported a difference in favour of DSCG.
Five of the studies had confidence intervals excluding the point of
no difference. Pooling the data (null hypothesis of homogeneity
rejected) resulted in an overall estimated difference of -0.24 daily
doses (WMD) favouring the DSCG group (95% CI -0.07 to -
0.42, random-effects model), which is statistically significant.
Figure 6. Forest plot of mean difference in bronchodilator use between sodium cromoglycate and placebo
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Steroid use in case of exacerbations was also addressed as an
outcome measure: systemic or inhaled, or sometimes unspeci-
fied. Seven studies provided these data (Table 8). Only one study
(Shioda 1970) found a significant difference. The pooled results
did not show a significant difference (OR 0.76, 95% CI 0.34 to
1.72).
Hospital admission
Hospital admission was reported in three studies (Table 9). None
of these found a significant difference betweenDSCGandplacebo.
Pooling the results of the parallel studies did not result in a signif-
icant difference (OR 0.93, 95% CI 0.40 to 2.56).
Lung function parameters
Thirteen studies assessed lung function parameters. Eight of these
reported no statistically significant difference between DSCG and
placebo groups/periods, sometimes without providing exact fig-
ures. The variety of parameters, methods used, time of day tests
were performed and the way they were presented made it impos-
sible to pool data. Five of the 13 studies reported differences to be
statistically significant for one or more lung function parameters
(Geller 1983; Hiller 1975; Limburg 1971; Matthew 1977; Yuksel
1992).
Side effects
Twelve studies did not report on side effects (Table 10). The re-
ported side effects of DSCG and placebo in the other 11 studies
were mild and of short duration (minutes to a few days). Overall,
differences between DCSG and placebo were small.
Subgroup analysis
Subgroup analyses were performed for four outcome measures:
day time wheeze (10 studies), overall asthma symptom/severity
score (10 studies), bronchodilator use (10 studies) and a combi-
nation of outcome measures using the same scale (19 studies, see
’Data collection and analysis’). For day time wheeze and for bron-
chodilator use, the differences between subgroups were either not
significant or one of the groups contained only one or two studies.
For the asthma symptom/severity score, the age of the children and
duration of follow up showed statistically significant differences.
Studies that included children with a mean age lower than five
showed less effect than studies that (also) included older children
(estimate of difference between DSCG and placebo -0.06 (95%
CI -0.15 to 0.02) versus -0.30 (95% CI -0.49 to -0.11), favouring
DSCG, P = 0.03). The three studies that had at least three months
follow up showed less effect than the eight shorter studies (0.04
versus 0.27, favouring DSCG, P = 0.01).
The combined outcome measure showed subgroup differences for
way of administration of the drug, hospitalisation, age and dura-
tion of follow up. Studies that applied nebulised DSCG showed
less effect than studies that used other methods of administration
(0.08 versus 0.32 on a 0 to 3 point symptom scale, P = 0.01).
Studies in hospitalised patients showed less effect than studies in
other patients (0.08 versus 0.34, P = 0.01). Subgroup analyses
for age and for duration of follow up both showed differences of
the same magnitude and in the same direction for the combined
outcome measure as reported above for asthma symptom/severity
score.
The subgroup analyses for the above mentioned four outcome
measures were also performed separately for studies with higher
methodological quality (see ’Data collection and analysis’ for cut-
offs). Comparing the results of this subgroup of studies to the
overall results revealed only minor differences, in the same direc-
tion as in our primary analysis, sometimes more in favour of the
subgroup of better quality studies.
The same analyses were done excluding cross-over studies that did
not take account of period effects (or did not report they did). For
the asthma symptom score (five studies) the pooled difference was
-0.06, with 95% CI (-0.16 to 0.03) (random-effects model). For
bronchodilator use (four studies) the pooled difference was -0.05
doses (-0.12 to 0.02) (fixed-effect), the random-effects model gave
-0.08 (-0.19 to 0.04), all not statistically significant. Both these
outcomes are smaller than found for thewhole group of studies (see
Tables). For the combined outcome measures (see ’Data collection
and analysis’) nine studies provided data. Themean difference was
-0.20, with random-effects, 95% CI -0.49 to 0.09.
Funnel plot
For the funnel plot, showing themean difference in effect between
DSCG and placebo treatment against precision of the study, we
could include 19 studies. The symmetry test gave a value of -
1.95 for the constant (SE 1.12, P = 0.09), which means that the
hypothesis of symmetrywas rejected. Especially imprecise (small or
heterogeneous) studies with results favouring placebo were under-
represented (Figure 7).
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Figure 7.
Meta-regression analysis and functional relationships
Seven study characteristics showed relationships with the (com-
bined) outcome variable (P < 0.25). As only 19 studies provided
data for this combined outcome measure, the power of a meta-
regression analysis would be very low. Furthermore, several study
characteristics were strongly related to each other (e.g. age, publi-
cation year, and method of administration of DSCG). Hence, we
decided to refrain from the planned analysis.
There was no influence of placebo symptom level on study out-
comes (day cough, day wheeze, overall severity score and bron-
chodilator use), assessed by means of functional relationships.
D I S C U S S I O N
Summary of main results
This systematic review, involving 1026 children in 23 trials per-
formed between 1970 and 1997, provides conflicting evidence re-
garding the superiority of DSCG over placebo in children with
asthma. There is no evidence to support the superiority of DSCG
over placebo in the percentage of symptom-free days, the main
outcome of this review, although this is limited by the small num-
ber of trials reporting on this outcome.
For several secondary outcomes, especially symptom scores and
bronchodilator use, we found significant group differences be-
tween DSCG and placebo, favouring DSCG. The overall treat-
ment effect for these outcomes appears to be quite small, with a
mean difference of 0.2 to 0.3 symptom score on a scale from 0 to
3 and less than ¼ puff per day for bronchodilator use. However,
considering the confidence intervals of the outcome measures, a
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clinically relevant effect of sodium cromoglycate cannot be ex-
cluded.
For mild persistent asthma, evidence is only available for children
below the age of four. For this subgroup, we can rule out important
benefit in terms of symptom scales but not in terms of symptom-
free days. We cannot rule out the possibility that DSCG is of
benefit in children above the age of four.
Overall completeness and applicability of
evidence
AlthoughDSCGhas been advocated asmaintenance treatment for
mild to moderate asthma, and nowadays only for mild persistent
asthma (GINA 2005), nearly all trials were hospital based, and
included children with moderate to severe asthma. Three studies
appear to have included a considerable proportion of childrenwith
mild asthma (Edmunds 1980; Furfaro 1994; Tasche 1997). The
study by Edmunds showed positive outcomes on four outcome
measures but was methodologically weak. The two other studies
had negative conclusions, i.e. DSCG was not more effective than
placebo. Both studies were carried out in young children (below
the age of four). Studies in children above the age of five found
more favourable effects than studies in children below that age.
In nine studies, the drug was administered with a nebuliser. Spin-
halers were used in eight studies.Metered dose inhalers with spacer
devices, nowadays the preferred method of administration for
young children,were used in only two studies (Tasche 1997; Yuksel
1992). The method of administration, a critical factor in delivery
of drugs to the lungs, was a predictor of outcome (combined out-
come measure): studies that used nebulisation showed less effect
than studies that used other methods.
The year of publication of the study and the age of the children
turned out to be strongly related. In multivariate analysis, results
proved to be instable, sometimes favouring age, sometimes pub-
lication year. It is impossible to disentangle these two factors: in
the early days of DSCG, studies were carried out in older children
and only after 1977 did studies start to include children below the
age of four.
Quality of the evidence
Heterogeneity of study results is apparent for several outcome
measures. The methodological quality of the studies, especially
regarding sequence generation and concealment of allocation, was
often impossible to assess (see ’Risk of Bias’ table Figure 1), and
varied considerably for other aspects.
The absence of small trials favouring placebo, as shown in the
funnel plot, indicates possible publication bias. This bias is likely
to result in an overestimation of the efficacy of DSCG, especially
because when applying a random-effects model the small positive
studies we included received a relatively large weight.
Potential biases in the review process
It has been questioned whether the (difference in) percentage of
symptom-free days should be the primary outcomemeasure, given
the fact that only a minority of studies included this (see Feedback
(Edwards et al)). However, we believe that the choice of primary
outcome measure should not be driven by availability, but by clin-
ical relevance. We feel supported by national and international
guidelines, where the aim of the treatment of asthma focuses on
leading a normal life with few or no complaints.
Lung function parameters could not be aggregated due to incom-
plete reporting of data.
Agreements and disagreements with other
studies or reviews
The effects of treatment with DSCG have been reviewed previ-
ously. As early as 1974 a narrative review was published in JAMA
(Dykes 1974), based on data provided by the manufacturers, but
giving no references to published data. Edwards 1994 examined
the evidence for the anti-inflammatory action of DSCG in adults
and children in a large number of controlled and uncontrolled
studies but it is unclear how these were selected. Hoag 1991 sum-
marised studies on the effect of DSCG on bronchial hyperre-
activity in adults and children. Schweitzer 1994 discussed the
role of DSCG in children below two years of age and concluded
that evidence was lacking; this conclusion was shared by Carlsen
1996. Holgate 1996 reviewed recent trials with metered dose in-
halers in children and adults and discussed challenge studies, ther-
apeutic studies, and the long-term effects of DSCG. Other re-
views were Berman 1983; Carlsen 1996; Church 1985; Kuzemko
1989; Shapiro 1985; Storms 2005. None of the reviews men-
tioned above were systematic, assessed the methodological quality
of studies or tried to quantify treatment effects. With the excep-
tion of Schweitzer 1994, all of these reviews came to conclusions
in favour of DSCG.
Our group published a systematic review of inhaled DSCG as
maintenance therapy in children in 2000 (Tasche 2000). The cur-
rent review differs from the previous one in several respects. Seven
studies that were included in the previous review were excluded
in this one, either because of different exclusion criteria, espe-
cially regarding continuous use of steroids (Crisp 1974; Fox 1972;
Hyde 1973; Miraglia 1982; Sly 1970), or because we initially
overlooked the fact that the placebo drug contained isoprenaline
and hence was not a true placebo (Silverman 1972; Smith 1968).
The current review included six studies that were not included
in the previous one, because of more thorough searching and the
withdrawal of language restrictions (Easton 1973; Dalene 1977;
Kobayashi 1970; Mikawa 1986; Smith 1970; Tuchinda 1974).
Another important difference is that the previous review only con-
sidered symptom scores for cough and wheeze as outcome mea-
sures. The overall results of the previous and the first version of
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the current review are similar. For the 2007 update, changing our
focus for the pooled results from the tolerance interval to the ran-
dom-effects model interval has slightly affected the interpretation
of our results in favour of DSCG. For this update, we excluded
Kraemer 1993, for reasons mentioned above.
The funnel plot was similar to the one published in our earlier
review (for ’wheeze’), although a different outcome was used in
order to include as many studies as possible (Figure 7). As we have
put forward before, when discussing our previous review (Tasche
2000; Tasche 2001), publication bias may be an explanation for
the asymmetry. More specifically we think it is possible that small
studies that did not find a beneficial effect for DSCG may not
have been submitted to journals, or may not have been published.
In order to appreciate the results of this review in the context of
other relevant treatments for childhood asthma, we refer to several
recently published Cochrane reviews (Adams 1999; Arnold 2008;
Guevara 2006; Gøtzsche 2008; Manning 2008; Seddon 2006;
Sridhar 2006).
The possibility of publication bias could be further explored by
trying to obtain information about studies that have been per-
formed but were never published. However, since most studies
we traced were published more than 20 years ago, and expecting
unpublished studies to be at least as old, this does not appear to
be a very promising endeavour.
This review only addressed DSCG as maintenance therapy in
childhood asthma. Other studies have investigated the role of
DSCG in attenuating exercise-induced bronchoconstriction, but
we are unaware of a systematic review comparingDSCGtoplacebo
for this condition. Indirect evidence from two systematic reviews
in this area suggests that DSCG may be beneficial in both adults
and children (Kelly 2003; Spooner 2003).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A considerable number of trials has been performed. Together,
they show heterogeneous effects for DSCG compared to placebo
as maintenance therapy for childhood asthma. Given the strong
indication of publication bias, the small overall treatment effect,
and the pooled confidence intervals including zero for our primary
outcome measure and several others, we conclude that it is not
justified to recommend DSCG as first line maintenance therapy
in childhood asthma. This recommendation is further supported
by the availability of alternatives with proven effectiveness, i.e.
inhaled corticosteroids. Formild persistent asthma evidence is only
available for children below the age of four. For this subgroup,
there is no good evidence that DSCG is much more effective than
placebo.We cannot rule out the possibility thatDSCG is of benefit
in older children.
Implications for research
Given the place of DSCG in current guidelines, the lack of studies
in children from age four onwards with mild persistent asthma is
surprising. A large parallel study in this group, of high method-
ological quality and extended followup (at least sixmonths), could
fill this gap. Preferably, such a study should not only compare
DSCG to placebo, but also contain a study arm with low dose
inhaled steroids. As the primary outcome measure we would rec-
ommend symptoms, either as a symptom score or as a percent-
age of symptom-free days. Given ongoing concern about the side
effects of inhaled steroids, such a study should also address sec-
ondary outcomes like growth, adrenal function and bone density.
Leukotriene-modifying drugs would be another class of drugs that
could be compared to DSCG.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bertelsen 1986
Methods DESIGN Parallel-group
METHODOLOGICAL QUALITY Chalmers score 31/95; Jadad score 3
WITHDRAWALS/ DROPOUTS 5
Participants SETTING Hospital outpatients?
AGE 1 to 4 years
INCLUSION CRITERIA Recurrent wheezy bronchitis demanding treatment at least
once a month during preceding winter or later
N = 59
Interventions 4 to 8 weeks baseline
10 weeks treatment









Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
Low risk 10 weeks: 5/59 missing, reasons provided,
well balanced across groups
Free of selective reporting? Unclear risk Protocol not available
Free of other bias? Unclear risk Unclear
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Cogswell 1985
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 43/91; Jadad score 4
WITHDRAWALS/ DROPOUTS 3
Participants SETTING Hospital outpatients?
AGE 1 to 4 years
INCLUSIONCRITERIA Regular attacks of asthma that required at least one admission
to hospital
N = 27
Interventions 4 weeks baseline, 2 x 26 weeks cross-over treatment
4 dd 20 mg nebulised








Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Low risk Quote: ’packaged in identical ampoules’
Blinding?
All outcomes
Low risk Quote: ’double-blind’ and ’identical am-
poules’
Incomplete outcome data addressed?
All outcomes
Low risk 24/27 analysed, reasons for withdrawal
provided, seems unbiased
Free of selective reporting? High risk Protocol not available, choice of one out-
come (symptom free days) seems post-hoc
(see Discussion)
Free of other bias? Unclear risk unclear
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Collins 1971
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 39/94; Jadad score 2
WITHDRAWALS/ DROPOUTS 0
Participants SETTING Hospital outpatients?
AGE 7 to 17 years
INCLUSION CRITERIA Severe allergic asthma, wheeze at least once a week
N = 14
Interventions 2 weeks baseline
2 x 4 weeks cross-over treatment
4 dd 20 mg Spinhaler
Outcomes Daily symptom scores
Clinical assessment
Lung function
Notes Nr. of patients differs from previous version of review, due to patients on steroids
Study provided no data for meta-analysis due to incomplete reporting
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned




Low risk Quote: ’double-blind’ ’physicians nor par-
ents’
Incomplete outcome data addressed?
All outcomes
Low risk Apparently no missing data
Free of selective reporting? High risk No results of hemograms, BUNandSGOT
Free of other bias? Unclear risk Unclear
Dalene 1977
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 32/91; Jadad score 3
WITHDRAWALS/ DROPOUTS 2
Participants SETTING Hospital outpatients?
AGE 1 to 4 years
INCLUSION CRITERIA Repeated episodes of virus induced asthma
N = 20
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Dalene 1977 (Continued)
Interventions 2 x 10 weeks
Cross-over treatment







Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
High risk 2/20 did not complete, unclear in which
group
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk Unclear
Easton 1973
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 35/87 = 40%; Jadad score 2
WITHDRAWALS/ DROPOUTS 0
Participants SETTING Hospital outpatients?
AGE Children of unspecified age
INCLUSION CRITERIA Daily extrinsic asthma, stable symptoms, total blood
eosinophil counts > 500 cells/cu mm
N = 25
Interventions Baseline period unspecified
2 x 3 weeks cross-over treatment
4 dd 20 mg capsule
Outcomes Total eosinophil count
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Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote ’double-blind’ and ’identical
placebo’
Incomplete outcome data addressed?
All outcomes
High risk One patient seemsmissing fromfigure.Not
mentioned in text
Free of selective reporting? Unclear risk Protocol not available
Free of other bias? Unclear risk Unclear
Edmunds 1980
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 29/91; Jadad score 2
WITHDRAWALS/ DROPOUTS 0
Participants SETTING Hospital outpatients?
AGE 5 to 15 years
INCLUSION CRITERIA Perennial asthma
N = 30
Interventions 3 x 4 weeks (incl. additional treatment)
Cross-over





Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
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Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
Unclear risk N of results is unclear
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk Unclear
Furfaro 1994
Methods DESIGN Parallel-group
METHODOLOGICAL QUALITY Chalmers score 56/95; Jadad score 4
WITHDRAWALS/ DROPOUTS 6
Participants SETTING Outpatients referred to pulmonary clinic
AGE 0 to 1 years
INCLUSION CRITERIA Chronic pulmonary symptoms for at least one month and
wheezing documented by a physician + symptoms in baseline period
N = 37
Interventions 3 weeks baseline, 6 weeks treatment




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Table of random numbers
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
High risk 3 parental withdrawn, 3 poor compliance,
group assignment of these children unclear
Free of selective reporting? Low risk Comprehensive listing of outcome mea-
sures
Free of other bias? Unclear risk No details
31Inhaled sodium cromoglycate for asthma in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Geller 1982
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 34/91 = 37%; Jadad score 4
WITHDRAWALS/ DROPOUTS 5
Participants SETTING Hospital outpatients?
AGE 0 to 2 years
INCLUSION CRITERIA Frequent troublesome wheezy bronchitis despite regular
bronchodilator therapy + symptoms in baseline period
N = 49
Interventions 2 weeks baseline
2 x 4 weeks cross-over treatment




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’, ’matching placebo’
Incomplete outcome data addressed?
All outcomes
High risk 44/49 analysed, ’one withdrawn while fail-
ing to improve during placebo period’
Free of selective reporting? Unclear risk Protocol not available
Free of other bias? Unclear risk Unclear
Geller 1983
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 41/90; Jadad score 4
WITHDRAWALS/ DROPOUTS 5
Participants SETTING Hospital outpatients?
AGE 4 to 13 years
INCLUSION CRITERIA Moderately severe or severe extrinsic asthma for at least 12
months, not taken DSCG or steroids for at least 6 months before trial
N = 48
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Geller 1983 (Continued)
Interventions 2 weeks baseline
2 x 6 weeks treatment




Patients’, parents’ and physicians’ preferences
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
High risk 43/48, 5 withdrawn, ’one failed to improve
on placebo’
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk Unclear
Glass 1981
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 29/94; Jadad score 2
WITHDRAWALS/ DROPOUTS 0
Participants SETTING Hospital outpatients?
AGE 1 to 4 years
INCLUSION CRITERIA Poor control of asthma under routine treatment
N = 16
Interventions 4 weeks baseline, 3 x 8 weeks cross-over treatment incl. additional study arm
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Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
High risk Tables seem to be based on fewer than 16
children (first sentence Results)
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk Unclear
Henry 1984
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 23/94; Jadad score 2
WITHDRAWALS/ DROPOUTS 3
Participants SETTING Hospital outpatients?
AGE 0 to 1 years
INCLUSION CRITERIA Suffered from recurrent attacks of wheezing, asthma consid-
ered troublesome by paediatricians and parents
N = 23
Interventions 2 weeks baseline, 3 x 8 weeks cross-over treatment incl. additional study arm




Notes Number of withdrawals probably higher
Risk of bias
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Henry 1984 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
Unclear risk 20/23 analysed, unclear whether with-
drawal was related to outcome
Free of selective reporting? High risk Biased description of favourable results in
some individual patients (p. 56)
Free of other bias? Unclear risk Unclear
Hiller 1975
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 44/87; Jadad score 4
WITHDRAWALS/ DROPOUTS 2
Participants SETTING Hospital outpatients?
AGE 9 to 13 years
INCLUSION CRITERIA Chronic perennial asthma, symptoms inadequately con-
trolled by DSCG and bronchodilators
N = 11
Interventions 4 x 1 month cross-over treatment, including 2 additional treatment arms
4 dd 20 mg Spinhaler





Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Low risk Quote: ’packed and coded by manufactur-
ers’
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Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
High risk 2/23 withdrawn because of severe symp-
toms
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk Unclear
Hiller 1977
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 34/87; Jadad score 3
WITHDRAWALS/DROPOUTS 0
Participants SETTING Hospital outpatients?
AGE 2 to 4 years
INCLUSION CRITERIA Frequent troublesome asthma
N = 17
Interventions 1 week baseline
2 x 8 weeks cross-over treatment






Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Low risk Quote: ’coded by manufacturers’
Blinding?
All outcomes
Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
Unclear risk All children completed the trial, for 3 chil-
dren no peak flow
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
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Hiller 1977 (Continued)
Free of other bias? Unclear risk unclear
Hyde 1970
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 38/87; Jadad score 3
WITHDRAWALS/ DROPOUTS 3
Participants SETTING Hospital outpatients?
AGE 6 to 16 years
INCLUSION CRITERIA Duration of asthma > 1 year, definite symptoms before in-
clusion
N = 60
Interventions 2 x 3 weeks
Cross-over treatment
4 dd 20 mg Spinhaler







Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Low risk Quote: ’Labels code’ (p. 450-1)
Blinding?
All outcomes
Low risk Quote: ’double-blind’ and taste
Incomplete outcome data addressed?
All outcomes
Low risk 57/60 completed, withdrawals due to fail-
ure to cooperate or keep adequate records
Free of selective reporting? Low risk All outcomes seem to have been addressed
Free of other bias? Unclear risk unclear
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Kobayashi 1970
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 45/90; Jadad score 3
WITHDRAWALS/DROPOUTS 7
Participants SETTING Hospital outpatients
AGE 6 to 15 years
INCLUSION CRITERIA Moderate to severe asthma
N = 37
Interventions 1 to 2 weeks baseline
2 x 4 weeks cross-over treatment
3 dd 20 mg Spinhaler
Outcomes Daily symptom score
Physician’s and patient’s impression
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’ and ’code remained
unbroken’
Incomplete outcome data addressed?
All outcomes
Low risk 7/37 withdrawn, seemingly unrelated to
outcome
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk Unclear
Limburg 1971
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 45/94; Jadad score 3
WITHDRAWALS/ DROPOUTS 1
Participants SETTING Asthma centre, inpatients
AGE 6 to 16 years
INCLUSION CRITERIA Regular asthma symptoms
N = 30
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Limburg 1971 (Continued)
Interventions 2 x 4 weeks
4 dd 20 mg Spinhaler






Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’ and ’matching
placebo’
Incomplete outcome data addressed?
All outcomes
Low risk 1/30 withdrawn nothing to do with this
therapy (p. 368)
Free of selective reporting? Low risk All outcomes seem to have been reported
Free of other bias? Unclear risk unclear
Matthew 1977
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 29/87; Jadad score 3
WITHDRAWALS/ DROPOUTS 1
Participants SETTING Hospital outpatients
AGE 3 to 6 years
INCLUSION CRITERIA Severe chronic perennial asthma + symptoms in baseline
period
N = 10
Interventions 8 weeks baseline, 2 x 4 weeks cross-over treatment
4 dd 20 mg nebulised
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Matthew 1977 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk ’double-blind’ and ’placebo identical’
Incomplete outcome data addressed?
All outcomes
Unclear risk Initial number of patients unclear and
probably greater than 9 for which data are
reported (Nine children completed? p. 36)
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk unclear
Mikawa 1986
Methods DESIGN Parallel-group
METHODOLOGICAL QUALITY Chalmers score 43/92; Jadad score 5
WITHDRAWALS/DROPOUTS 49
Participants SETTING Hospital outpatients?
AGE 6 to 15 years
INCLUSION CRITERIA Mild to moderate asthma
N = 196
Interventions 2 weeks baseline
4 weeks treatment
4 dd 20 mg aerosol
Outcomes Symptom scores
Side effects
Patients’ and parents’ assessment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
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Mikawa 1986 (Continued)
Allocation concealment? Low risk Quote: ’randomly allocated six in a group,
key codes sealed and kept by controller’
Blinding?
All outcomes
Low risk Quote: ’double-blind’ and ’matching
placebo’
Incomplete outcome data addressed?
All outcomes
Low risk 145/196 completed. Reasons for exclusion
well described, these seemunrelated to out-
come (table 1)
Free of selective reporting? Low risk All outcomes seem to be reported
Free of other bias? Unclear risk Unclear
Shioda 1970
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 42/95; Jadad score 3
WITHDRAWALS/ DROPOUTS 1
Participants SETTING Hospital, inpatients and outpatients
AGE 6 to 15 years
INCLUSION CRITERIA Perennial asthma
N = 34
Interventions 2 x 4 weeks cross-over treatment
4 dd 20 mg Spinhaler







Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’ and ’neither pa-
tients, parents nor clinicians were aware’
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Shioda 1970 (Continued)
Incomplete outcome data addressed?
All outcomes
Low risk 1/34 withdrawn, unrelated to outcomes
(although probably a side-effect)
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk unclear
Smith 1970
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 43/92; Jadad score 4
WITHDRAWALS/DROPOUTS 3
Participants SETTING Hospital outpatients?
AGE 7 to 16 years
INCLUSION CRITERIA Hay fever and pollen asthma confirmed by skin prick tests
N = 18
Interventions 4 weeks
4 dd 20 mg Spinhaler
Outcomes Daily symptom scores
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk List of random numbers
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
Unclear risk 15/18 completed (368), unclear in which
group
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk unclear
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Tasche 1997
Methods DESIGN Parallel-group
METHODOLOGICAL QUALITY Chalmers score 75/95; Jadad score 3
WITHDRAWALS/ DROPOUTS 14
Participants SETTING General practice
AGE 1 to 4 years
INCLUSION CRITERIA Previously been prescribed asthma medication and meeting
criteria for moderate asthma
N = 232
Interventions 4 weeks baseline
22 weeks treatment
3 dd 10 mg aerosol + spacer (Aerochamber) + face mask





Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Low risk Quote: ’treatment allocation was concealed
fromparents, patients, GPs, research physi-
cian and nurses’ (p. 1061)
Blinding?
All outcomes
Low risk Quote: ’double-blind’
Incomplete outcome data addressed?
All outcomes
Low risk 167/218 completed study. Equally divided
and not related to primary outcome (Fig 1)
Free of selective reporting? High risk All outcome measures seem to be reported
Free of other bias? Unclear risk unclear
Tuchinda 1974
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 49/86; Jadad score 4
WITHDRAWALS/ DROPOUTS 0
Participants SETTING Hospital outpatients?
AGE 7 to 12 years
INCLUSION CRITERIA Chronic asthma
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Tuchinda 1974 (Continued)
N = 17
Interventions 2 x 4 weeks cross-over treatment







Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk Quote: ’double-blind’, ’identical in taste
and color’
Incomplete outcome data addressed?
All outcomes
Low risk All patients completed the study
Free of selective reporting? Unclear risk No results on symptoms
Free of other bias? Unclear risk Unclear
Yuksel 1992
Methods DESIGN Cross-over
METHODOLOGICAL QUALITY Chalmers score 32/91; Jadad score 2
WITHDRAWALS/DROPOUTS 0
Participants SETTING Hospital outpatients?
AGE 0 to 2 years
INCLUSION CRITERIA Preterm born, wheeze and/or cough 3 to 4 days/week for
previous 4 weeks + symptoms for at least 3 days following respiratory infections
N = 16
Interventions 2 to 3 weeks treatment
4 dd 5 mg
Aerosol + face mask (coffee cup)
Outcomes Daily symptom scores
Additional treatment
Lung function
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Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not mentioned
Allocation concealment? Unclear risk Not mentioned
Blinding?
All outcomes
Low risk ’double-blind’ and ’similarly shaped and
sized cannister’ (Yuksel 1993)
Incomplete outcome data addressed?
All outcomes
Low risk All 16 patients completed the study
Free of selective reporting? Unclear risk Protocol not available, planned outcome
measures unknown
Free of other bias? Unclear risk unclear
Assessment of concealment of allocation for cross-over studies applies only to initial allocation.
Adequacy of washout period not taken into account because of incomplete reports.
Possible unblinding due to perceived differences were not taken into account.
Setting = ? where not clearly stated, but deducted from authors’ affiliations.
dd: doses per day
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agbayani 1984 Double dummy, no placebo arm
Anastasatu 1979 Not an RCT
Anonymous 1969 Included adults as well, but no age specific results
Arndt 1975 Not placebo-controlled
Avital 1991 Theophylline versus placebo (cross-over, double dummy), no placebo arm
Berman 1975 Partly > 18 years, no separate results for children
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(Continued)
Bernstein 1972 Results for children not presented separately (except patient preference)
Continuous use of steroid was allowed
Blumenthal 1988 Results for children not presented separately
Bonifazi 1985 Age 10 to 50, results for children not presented separately
Booij-Noord 1971 Results for children not presented separately
DSCG not as maintenance therapy
Bruderman 1990 Not an RCT
Carrasco 1989 Results for children not presented separately
Carrà 2001 No placebo arm
Chai 1973 All children on steroids continuously
Chan-Yeung 1971 Only two children
Chyrek-Borowska 1975 Results for children not presented separately
Ciszek 1974 Results for children not presented separately
Crawford 1974 Incomplete report
Crawford 1974b Most children on steroids continuously (281 doses of 5 mg prescribed in 30 children for 4 weeks)
Crimi 1988 Not maintenance therapy (adenosine-induced bronchoconstriction)
Crisp 1974 Steroid use was one of the selection criteria, no separate results for non-users
Croce 1995 Patients 6 to 24 years
Results for children not presented separately
De Baets 1998 No placebo arm
Dickson 1969 Open study
Droszcz 1973 Ages 15 to 63 years
Results for children not presented separately
Edmunds 1994 No placebo arm
Engström 1975 No placebo for asthma treatment
Same data as Engström 1977
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(Continued)
Engström 1977 No placebo arm
Exline 1972 Results for children not presented separately
Forster 1998 Abstract only
Fox 1972 9 patients were on regular steroids, no separate results for non-users
Friday 1973 No information on age, included patients above 18 years, no age-specific results
Fuleihan 1973 Includes both adults and children, no separate results for children
Furukawa 1999 Results for children not presented separately
Garcio Velloso 1984 No information on age
Gaur 1997 No information on blinding (possibly not blinded), no placebo
Results on children not presented separately
Geller-Bernstein 198 No placebo arm
Gemicioglu 1993 Ages 15 to 46, results for children not presented separately
Glazer 1971 No information on age
Godfrey 1975 Study conducted in exercise-induced bronchoconstriction
Gomez-Orozco 1976 Not an RCT
Graber 1998 Not original, refers to Tasche 1997
Grifoni 1971 Age 5 to 63 years
Results for children not presented separately
Gulyas 1984 Combined therapy, not DSCG alone
Guminski 1976 No placebo arm
Haber 1989 Patients 16 to 41 years
Results for children not presented separately
Herjavecz 1982 No placebo arm
Results for children not presented separately
Hermance 1973 Steroid use was continued
Hobday 1970 No placebo arm (isoprenaline)
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(Continued)
Hyde 1971 Not an RCT
Hyde 1973 15 of 57 children were on daily steroids
Results for non-users not presented separately
Inoue 1970 No placebo arm
Irani 1972 Results for children not presented separately
Ito 1971 only one child below age of 18
Jenssen 1973 Results for children not presented separately
Johannessen 1975 Results for children not presented separately
Jones 1970 Single-blind
Kehnscherper 1993 No placebo arm
Kennedy 1969 Primary reference gives no information on age
Secondary reference gives 10 patients in age range 11 to 20, no specific data
Khurana 1977 Open study
Kidner 1968 Results for children not presented separately
Kimmel 1974 Open study
Klein 1980 No placebo arm
Klein 1981 No placebo arm
Knezevic 1997 (Abstract only)
No placebo arm
No information on randomisation
Kotaniemi 2005 Not blinded
Kraemer 1986 DSCG single-blind
Kraemer 1987 Single-blind with respect to SCG
Kraemer 1993 Daily use of bronchodilator in both arms, irrespective of symptoms
Kuzemko 1974 Study compares 2 active treatments
Placebo period not double-blind
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(Continued)
Kuzemko 1977 No placebo
König 1973 Not double-blind
No placebo period
Lahoz 1973 Adults
Lecks 1974 Included children > 17 years of age, probably above 18 years
Lenney 1978 Exercise induced asthma
Linehan 1970 Single-blind
Löwhagen 1985 Parallel-group trial with only 1 child
Macdonald 1979 Cromoglycate not compared to placebo
Mahashur 1981 Not double-blind, not randomised, no separate results for children
Marks 1974 Incomplete results: only patients who had benefit reported
Marshall 1969 Placebo-controlled study included both children and adults
Masood 1978 Results for children not presented separately
Matsumoto 1994 Not randomised
Mattoli 1986 Allergen-induced challenge
McLean 1973 Included children > 18 yearrs
Mellon 1982 No placebo arm
Menardo 1998 No placebo arm
Miraglia 1981 Not an RCT
Miraglia 1982 10 of 31 children use steroids continuously, no separate results for non-users
Mitchell 1976 No placebo arm
Moeller 2009 No placebo arm
Molema 1989 Results for children not reported separately
Moran 1968 Results for children not presented separately
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(Continued)
Muittari 1969 Not randomised
Munro Ford 1969 No information on age, probably adults
Naganathan 1975 37 patients age 11 to 53 years, 6 patients 11 to 20 years, no age-specific results
Ng 1977 Study compares 2 active treatments
Placebo period not double-blind
Orefice 1990 Not randomised
Pesic 1975 No placebo arm
Petersen 1996 No placebo arm
Price 1995 Not blinded, no placebo
Rafinski 1977 Not an RCT
Rauber 1983 No placebo arm
Reid 1988 Results for children not presented separately
Robertson 1969 Only 1 child
Romano 1970 No information on ages
Description of methods very incomplete
No useful results
Sarlet 1973 Not double-blind
No placebo arm
Schmidt 1973 No placebo arm
Selcow 1983 Not an RCT
Selcow 1989 Age 8 to 20 years
Results for children not presented separately
Sellars 1975 Age of children > 17 years, above 18?
Shioda 1973 Overlapping data with Shioda 1970, but no data on RCT
Shiota 1984 Adults only
Shore 1971 Not an RCT
Sienra Monge 1990 Not an RCT
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(Continued)
Silverman 1972 Not placebo-controlled (isoprenaline)
Sly 1970 2 of 21 children used prednisone continuously, results for non-users not presented separately
Smith 1968 Not placebo-controlled (isoprenaline)
Smith 1980 Not an RCT
So 1981 Aerosol compared to powder
No placebo
Ages 12 to 31
Streumer 1970 Incomplete description of methods, probably not a RCT
Thompson 1974 Age 7 to 28 years
Results for children not presented separately
Toshner 1974 16 patients were on continuous steroids
Turpeinen 2010 not randomised, no placebo arm
Varsano 1983 Upper respiratory tract infections, not asthma
Viscardi 1997 Not asthma
Watanabe 1992 Not an RCT
Weinbren 1969 Isoprenaline is not placebo
Wells 1979 Not maintenance therapy
Cat fur challenge
Wheatley 1981 No placebo arm
Zarkovic 1991 Open study
No placebo
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S





















6 13 23 6 7 6 24 10 95 (100%)
Bertelsen
1986
1 3 12 3 3 0 6 3 31/95 = 33%
Cogswell
1985
1 10 13 4 3 1/3 9/22 2 43/91 = 47%
Collins
1971
2 7 18 6 0 0 3 3/9 39/94 = 41%
Dalene
1977
2 2 16 4 3 1 3/20 2 32/91 = 35%
Easton
1973
1 4 17 5 1 0 4/16 3 35/87 = 40%
Edmunds
1980
0 4 14 0 1 2 6/20 2 29/91 = 33%
Furfaro
1994
3 13 13 5 4 3 11 4 56/95 = 59%
Geller
1982
1 4 16 2 3 0 6/20 2 34/91 = 37%
Geller
1983
2 6 18 3 4 1 5/19 2 41/90 = 46%
Glass 1981 0 4 14 2 0 1 6 2/9 29/94 = 31%
Henry
1984
0 0 16 3 0 0 2 2/9 23/94 = 24%
Hiller
1975
2 10 18 4 3 0 5/18 2/9 44/87 = 51%
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Table 1. Methodological quality scores according to Chalmers (Continued)
Hiller
1977
0 10 14 4 3 0 2/18 1/9 34/87 = 39%
Hyde 1970 1 6 13 4 3 0 6/18 5/9 38/87 = 44%
Kobayashi
1970
2 4 16 5 3 0 13/19 2 45/90 = 50%
Limburg
1971
1 4 13 5 3 0 11/23 8 45/94 = 48%
Matthew
1977
0 4 13 4 3 0 3/16 2 29/87 = 33%
Mikawa
1986
3 4 16 5 2 0 721 6 43/92 = 47%
Shioda
1970
3 6 18 4 2 0 5 4 42/95 = 44%
Smith
1970
2 4 16 6 3 0 4/21 8 43/92 = 47%
Tasche
1997
6 11 20 3 6 3 21 5 75/95 = 79%
Tuchinda
1974
1 5 19 6 3 0 11/15 4 49/86 = 57%
Yuksel
1992
3 4 16 5 3 0 5/21 3/9 39/91 = 43%
“/” means denominator adapted because items non-applicable.
Table 2. Methodological quality scores according to Jadad’s criteria
Study Randomisation Randomisation
detail
Double-blind Blinding details Withdrawals Total
Bertelsen 1986 1 0 1 0 1 3
Cogswell 1985 1 0 1 1 1 4
Collins 1971 0 0 1 1 0 2
Dalene 1977 1 0 1 0 1 3
Easton 1973 1 0 1 0 0 2
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Table 2. Methodological quality scores according to Jadad’s criteria (Continued)
Edmunds 1980 1 0 1 0 0 2
Furfaro 1994 1 1 1 0 1 4
Geller 1982 1 0 1 1 1 4
Geller 1983 1 0 1 1 1 4
Glass 1981 1 0 1 0 0 2
Henry 1984 0 0 1 0 1 2
Hiller 1975 1 0 1 0 1 3
Hiller 1977 1 0 1 1 1 4
Hyde 1970 0 0 1 1 1 3
Kobayashi 1970 1 0 1 0 1 3
Limburg 1971 0 0 1 1 1 3
Matthew 1977 1 0 1 1 0 3
Mikawa 1986 1 1 1 1 1 5
Shioda 1970 1 0 1 0 1 3
Smith 1970 1 1 1 0 1 4
Tasche 1970 1 0 1 0 1 3
Tuchinda 1974 0 1 1 1 1 4
Yuksel 1992 1 0 1 0 0 2
Yuksel 1993 1 0 1 0 1 3
Table 3. Primary outcome: percentage of symptom-free days





Diff (c-p) SE paper SE imputed
or paper






24 0.34 0.34 11.10 5.10 5.10 0.50 21.70 -
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Table 3. Primary outcome: percentage of symptom-free days (Continued)
Edmunds
1980
30 0.25 0.25 15.00 7.50 7.50 -0.32 30.32 -
Henry
1984




218 0 0 -1.60 3.10 3.10 -7.70 4.60 -
Homogeneity test Chi2 = 7.48, P = 0.06
Pooled results mean (95%
CI)
Fixed-effect model 3.57 (-1.18 to 8.32)
Random-effects model 6.76 (-2.18 to 15.70)
Rho = correlation between DSCG and placebo period (cross-over studies).
NA = not available in paper.
Table 4. Day cough score















58 0 0 0.08 0.13 0.13 -0.17 0.33 -
Cogswell
1985
24 NA NA -0.09 0.05 0.05 -0.19 0.01 -
Dalene
1975




44 NA 0.63 -0.14 NA 0.13 -0.40 0.12 Shioda
1970
Glass 1981 14 NA NA -0.09 0.39 0.39 -0.93 0.76 -
Henry
1984




17 NA NA -0.18 0.08 0.08 -0.34 -0.01 -
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Table 4. Day cough score (Continued)
Shioda
1970
33 0.63 0.63 -0.65 0.12 0.12 -0.89 -0.40 -
Smith
1970
18 0 0 -0.45 0.28 0.28 -1.05 0.14 -
Homogeneity test Chi2 = 23.44, P < 0.001
Pooled results: mean (95%
CI)
Random-effects model -0.18 (-0.32 to -0.04)
NA = not available in paper.
Table 5. Day wheeze score















58 0 0 0.06 0.12 0.12 -0.17 0.30
Cogswell
1985
24 NA NA -0.09 0.05 0.05 -0.21 0.01
Dalene
1975




44 NA 0.34 -0.25 NA 0.19 -0.63 0.13 Matthew
1977
Glass 1981 14 NA NA 0.02 0.04 0.04 -0.07 0.11
Henry
1984








8 0.26 0.26 -0.54 0.18 0.18 -0.94 -0.14
Smith
1970
18 0 0 -0.45 0.16 0.16 -0.82 -0.08
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Table 5. Day wheeze score (Continued)
Yuksel
1993
16 0.34 0.34 -0.31 0.15 0.15 -0.63 0.01
Homogeneity test Chi2 = 23.47, P = 0.01
Pooled results: mean (95%
CI)
Random-effects model -0.11 (-0.19 to -0.03)
NA = not available in paper.
Table 6. Overall symptom/severity score
















24 NA NA -0.12 0.05 0.05 -0.22 -0.02 -
Edmunds
1980
30 NA NA -0.13 0.04 0.04 -0.21 -0.05 -
Furfaro
1994
31 0 0 0.17 0.22 0.22 -0.28 0.62 -
Geller
1982
44 NA 0.70 -0.20 NA 0.13 -0.46 0.06 Hyde 1970
Geller
1983
46 NA NA -0.45 0.19 0.19 -0.83 -0.07 -
Henry
1984




9 NA NA -0.24 0.05 0.05 -0.35 -0.13 -
Limburg
1971
27 0.67 0.67 -0.18 0.07 0.07 -0.34 -0.03 -
Shioda
1970
33 0.70 0.70 -0.94 0.11 0.11 -1.17 -0.70 -
Tasche
1997
218 0 0 0.01 0.05 0.05 -0.09 0.11 -
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Table 6. Overall symptom/severity score (Continued)
Homogeneity test Chi2 = 70.76, P < 0.001
Pooled results: mean (95%
CI)
Random-effects model -0.22 (-0.34 to -0.09)
NA = not available in paper.
Table 7. Bronchodilator use (number of doses per day)
















58 0 0 -0.33 0.20 0.20 -0.73 0.07 -
Dalene
1977




30 0.50 0.50 -0.29 0.08 0.08 -0.45 -0.13 -
Glass 1981 14 NA NA 0.05 0.04 0.04 -0.04 0.14 -
Henry
1984




25 NA NA -0.20 0.09 0.09 -0.40 0.00 -
Matthew
1977
25 0.92 0.92 -0.64 0.16 0.16 -1.01 -0.27 -
Shioda
1970
33 0.79 0.79 -0.75 0.08 0.08 -0.91 -0.59 -
Smith
1970
15 0 0 -0.02 0.05 0.05 -0.13 0.10 -
Tasche
1997
218 0 0 0.01 0.07 0.07 -0.13 0.16 -
Homogeneity test Chi2 = 116.06, P < 0.001
58Inhaled sodium cromoglycate for asthma in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 7. Bronchodilator use (number of doses per day) (Continued)
Pooled results: mean (95%
CI)
Random-effects model -0.24 (-0.42 to -0.07)
NA = not available in paper.
Table 8. Steroid use (ln (OR steroid) DCSG/placebo)













Glass 1981 14 NA NA -4.96 8.14 8.14 -20.91 11.00 -
Hyde 1970 42 NA NA -0.69 0.88 0.88 -2.41 1.03 -
Kobayashi
1970
25 NA NA -3.91 6.63 6.63 -16.90 9.08 -
Limburg
1971
27 NA NA -3.61 5.66 5.66 -14.70 7.48 -
Shioda
1970
33 NA NA -1.95 0.87 0.87 -3.66 -0.24 -
Smith
1970
15 0 0 -5.40 12.92 12.92 -30.72 19.92 -
Tasche
1997
218 0 0 -0.17 0.39 0.39 -0.93 0.59 -
Combining parallel studies (Smith and Tasche)
Homogeneity test Chi2 = 0.57, P = 0.45
Pooled results: mean (95%
CI) (ln (OR))
Fixed-effect model -0.27 (-1.09 to 0.54)
(0 = no difference) Random-effects model -0.27 (-1.09 to 0.54)
Pooled results: mean (95%
CI) OR
All models 0.76 (0.34 to 1.72)
(1 = no difference)
NA = not available in paper.
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Table 9. Hospital admittance (ln (OR hospital) DSCG/placebo)















58 0 0 -0.07 0.55 0.55 -1.17 1.03 -
Furfaro
1994
31 0 0 -0.07 1.46 1.46 -2.97 2.85 -
Glass 1981 14 NA NA NA NA 8.14 -20.91 11.00 -
Pooling parallel studies (Bertelsen and Furfaro)
Homogeneity test Chi2 = 0, P = 1.0
Pooled results: mean (95%
CI) (ln (OR))
Fixed-effect model -0.07 (-1.08 to 0.94)
(0 = no difference) Random-effects model -0.07 (-1.08 to 0.94)
Pooled results: mean (95%
CI) OR
All models 0.93 (0.40 to 2.56)
(1 = no difference)
NA = not available in paper.
Table 10. Side effects reported in included studies
Study ID Side effects DCSG Side effects placebo
Bertelsen 1986 Eczema oral (1)
Cough (1)
Cough (3)
Cogswell 1985 Not mentioned Not mentioned
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Table 10. Side effects reported in included studies (Continued)
Dalene 1977 Not registered Not registered
Easton 1973 Not mentioned Not mentioned
Edmunds 1980 Nausea, vomiting, abdominal pain, headache 5% Nausea, vomiting, abdominal pain, headache 5%
Furfaro 1994 Not mentioned Not mentioned
Geller 1982 Not mentioned Not mentioned
Geller 1983 None Throat irritation (1)
Glass 1981 Well-tolerated Well-tolerated
Henry 1984 Not mentioned Not mentioned
Hiller 1975 Not mentioned Not mentioned
Hiller 1977 Not mentioned Not mentioned








Kobayashi 1970 No side effects No side effects
Limburg 1971 Cough (2) Cough (1)
Matthew 1977 Not mentioned Not mentioned
Mikawa 1986 Mild nausea (1) Mild nausea (1)





Smith 1970 Not mentioned Not mentioned
Tasche 1997 Mild side effects (40)
Eczema mask (5)
Cough after inhalation (9)
Mild side effects (33)
Eczema (0)
Cough after inhalation (1)
Tuchinda 1974 No side effect experienced No side effect experienced
Yuksel 1992 Not mentioned Not mentioned
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Table 10. Side effects reported in included studies (Continued)
Yuksel 1993 Not mentioned Not mentioned
F E E D B A C K
Criticism of conclusions and methods
Summary
1. The primary outcome measure, symptom free days is directionally in favour of SCG in 3 of 4 studies. The results are dominated by
one study in which we doubt whether the dosage was adequate.
2. Of the 16 secondary outcome measures, 8 were statistically significant in favour of SCG. None were in favour of placebo.
3. Of the 17 outcome measures, 11 are to be found in less than 5 studies. Of the 6 outcome measures that included 5 or more studies,
4 are statistically significantly in favour of SCG. None are in favour of placebo.
4. The presentation of the results is misleading.
5. Three methods of drug delivery are included with a dose range of 1 mg 3 times daily to 40 mg 3 times daily. No account is taken of
the consequences of efficacy on this dose range. There is ample evidence that 2 of the delivery systems, pMDI and nebulization may
not provide an adequate dose particularly in children below the age of 5 years.
6. The diagnosis of asthma is difficult to make with confidence in children below the age of 5 years. At least half the included studies
are in children in this age group. Drug delivery also presents problems in this age group.
7. A number of relevant studies have been excluded. We have identified 16 studies that should have been included. Five were excluded as
they apparently included subjects over the age of 17 years. Our examination of the papers shows this either not to be the case or results
for subjects below 18 years were presented separately. These studies should have been included. The exclusion of studies due to some
children being on regular steroid therapy is not justified in those studies in which the steroid dose was kept fixed. If this exclusion was
consistent, 2 further studies should have been excluded. It is doubtful if the exclusion of studies in which a fixed dose of bronchodilator
was added to both SCG and placebo treatment arms is justified if this review is considered to be representative of SCG in childhood
asthma.
Reply
We have replied to most of these criticisms before in response to letters by Edwards et al (2002), commenting on a previous version
of our review, published in Thorax. Our conclusions are based on both the fact that the confidence interval that we a priori chose to
be our guidance (the tolerance interval) does include ’no effect’ for most of the outcome measures as well as the strong suspicion of
publication bias, as reflected in the funnel plot.
The fact that the diagnosis of asthma is difficult in young children and drug delivery may pose problems, does not mean that doctors
should not treat these children, nor does it mean that investigators should not assess the effectiveness of therapeutic options in this
group of children. The protocol of our review was clear in excluding studies that included patients over the age of 17 years. In this
update, we excluded the study by Kraemer et al for the reasons suggested by the authors of the criticism.
Contributors
JBLHowell, MT Stevens, AMEdwards, N Åberg, B Callaghan, S Godfrey, STHolgate, P König, AMorikawa, D Reinhardt, B Stenius-
Aarniala, JO Warner, Weinberg
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Criticism of updated review, 7 July 2010
Summary
The current version of the review addresses many concerns which we submitted as a comment previously. We thank the authors for
addressing our comments and producing a clearer presentation of the results of their work.
Our criticisms of this review, the previous review and earlier papers on which they were based relate to the statistical methods used,
the presentation of the data the interpretation of the data and the conclusions drawn. A full account of our criticisms can be found in
paper by three of us [1]. This was accompanied by two commentaries by statisticians in the same journal [2,3].
The first Cochrane review concluded that ’The evidence of the efficacy of sodium cromoglicate (DSCG) over placebo is not proven’.
In the latest review, the conclusion is ’There is insufficient evidence to be sure about the efficacy of (DSCG) over placebo’. This is
a justified shift in stance, but still understates the case for DSCG. Although there was no statistically significant difference between
DSCG and placebo on the primary outcome (symptom-free days), seven secondary outcome variables for which data were available in
four or more studies were, according to the authors, all in favour of DSCG, and six were statistically significant. Rather than providing
’conflicting evidence regarding the superiority of DSCG over placebo’ we believe the review provides overwhelming evidence for the
efficacy of DSCG compared to placebo. We do not believe that the authors have fully justified their choice of the primary outcome,
given the low power of the of this outcome in that only four studies were included, and one study dominated these results. In one of the
commentaries to our paper the author states ’it seems inappropriate to put major emphasis on the meta-analysis of a primary outcome
that is reported in very few of the trials’ [3] They have also not provided an evidence-based response to the criticism that the dose used
in this study was probably inadequate.
The authors claim that there may be publication bias, yet this is only weakly supported by their funnel plots which are potentially
subject to criticism as they include different outcome variables.
The size of the overall treatment effect is claimed to be small but should be viewed in the light of the mild symptoms experienced by the
children. On-treatment mean symptom scores, where given, were less than one (on a 0-3 scale) in both DSCG and placebo treatment
groups. Given the relatively low margin for improvement, the treatment effects seen are indeed relevant.
Based on the above, it is surprising that the authors conclude that ’it is not justified to recommend DSCG as first line therapy in
childhood asthma’ (the objective was in any case to assess maintenance therapy). The drug has established evidence of safety and efficacy
in a wide number of indications, and has a role in both first line and maintenance therapy.
The authors conclude that ’a clinically relevant effect of DSCG cannot be excluded’. We suggest that this review provides strong support
for the beneficial effect of DSCG over placebo in childhood asthma, particularly those over four years of age.
1. Stevens MT, Edwards AM, Howell JBL. Sodium cromoglicate: an ineffective drug or meta-analysis misused? Pharmaceut Statist
2007; 6: 123-137.
2. Lewis S, Deeks J. Re Sodium Cromoglicate: An Ineffective Drug or Meta-analysis Misused? Pharmaceut. Statist. 2007; 6: 139-140
3. Lewis JA. Comment on sodium cromoglicate: an ineffective drug or meta-analysis misused? by Stevens et al.; Pharmaceut. Statist.
2007; 6: 141-143
Reply
We thank Dr Edwards and colleagues for their continued interest in our review. The points raised in their comment are not new, and we
have carefully considered thesewhen updating our review. Aswe have already clarified in previous replies, changing the primary endpoint
of our review due to its infrequent availability relative to other measurements in the studies would violate elementary methodological
principles.
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WH A T ’ S N E W
Last assessed as up-to-date: 27 July 2010.
Date Event Description
17 November 2010 Feedback has been incorporated Feedback has been received and appended to the review. The authors have
responded to the feedback, but there have been no changes made to the
review
H I S T O R Y
Protocol first published: Issue 1, 2001
Review first published: Issue 3, 2003
Date Event Description
28 July 2010 New search has been performed Literature search re-run, no new included studies
found. Two new excluded studies found
7 October 2009 New search has been performed Litertaure search re-run; no new studies found.
27 February 2009 Amended Risk of bias tables completed, copy edited table of in-
cluded study
25 October 2008 New search has been performed In response to external peer review:
Modified overall description of outcomes, not exclud-
ing a clinically relevant benefit.
Added forest plots based on values provided in Addi-
tional tables 3-19, we could not use the forest plots
provided in RevMan, as we assumed a t-distribution
when calculating confidence intervals for individual
studies.
Yuksel 1992 and 1993 combined, as these papers refer
to the same study
30 May 2008 Amended Converted to new review format.
19 December 2007 New citation required and conclusions have changed In response to comments by Edwards et al, one study
was excluded (Kraemer (1993)).
Searches performed for years 2003-2007 did not reveal
any new studies, but did lead to new ’excluded studies’.
Paragraph and table added on side effects as reported
in included studies.
Paragraph ’other reviews’ in Discussion was extended.
Tolerance intervals for pooled results removed.
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(Continued)
Risk of Bias tables added.
Discussion rewritten.
1 November 2007 New search has been performed Literature search re-run in November 2007
C O N T R I B U T I O N S O F A U T H O R S
JCvdW drafted text of protocol and review.
MJAT, JHJMU and JCvdW searched papers, assessed inclusion criteria and methodological quality.
RMDB and JCvdW extracted data. RMDB performed statistical analysis.
JHJMU and JCvdW drafted the 2008 update.
All authors commented on versions of the protocol and review.
D E C L A R A T I O N S O F I N T E R E S T
The authors were involved in a placebo-controlled trial (Tasche 1997) and in an earlier systematic review comparing DSCG and placebo
(Tasche 2000). Both studies had negative conclusions.
S O U R C E S O F S U P P O R T
Internal sources
• Department of General Practice, Erasmus MC - University Medical Center Rotterdam, Netherlands.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Asthmatic Agents [∗therapeutic use]; Asthma [∗drug therapy]; Cromolyn Sodium [∗therapeutic use]; Randomized Controlled
Trials as Topic
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